{"id":"56c24d25-b9c6-5088-8539-20392fa44c35","stable_key":"79018983-9179-5c1a-8e7a-d6f47a13582b:ki-mmi15","predicate":"promotes_normalization_of","statement":"With MMI 15 mg, two-week FT4 normalization was 54% with KI versus 27% without it.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"698f8209-3604-508e-a5df-044de4691935","mechanism_event_label":"The lower-methimazole comparison also showed faster control.","subject":{"id":"d6a7fe6a-d90e-5fad-acf4-4971b24fa8d7","slug":"potassium-iodide","display_name":"Potassium iodide","entity_type_key":"chemical_species"},"object":{"id":"5554c435-1309-5f33-bf47-6cf03cdff963","slug":"serum-free-t4-concentration","display_name":"Serum free thyroxine concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"698f8209-3604-508e-a5df-044de4691935","stable_key":"79018983-9179-5c1a-8e7a-d6f47a13582b:ki-mmi15-event","event_type":"observed_relationship","label":"The lower-methimazole comparison also showed faster control.","description":"With MMI 15 mg, two-week FT4 normalization was 54% with KI versus 27% without it.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"d6a7fe6a-d90e-5fad-acf4-4971b24fa8d7","slug":"potassium-iodide","display_name":"Potassium iodide","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"5554c435-1309-5f33-bf47-6cf03cdff963","slug":"serum-free-t4-concentration","display_name":"Serum free thyroxine concentration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"a3a516d1-65de-5638-8baa-bf4571450959","slug":"methimazole","display_name":"Methimazole","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"experimental_model","value_text":"134 untreated Graves patients randomized to MMI 15 or 30 mg, with or without KI; KI withdrawn after FT4 normalization.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure_category","value_text":"Study-specific exposure, including pharmacological and in-vitro conditions; normal is the schema fallback outside the three availability categories.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Combination treatment, not KI monotherapy; KI dose not extracted from abstract. Faster biochemical control does not prove lasting remission.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Potassium iodide research collection; shared-anion and comparator studies are not all KI interventions.","comparator":null,"unit":null,"notes":"","entity":{"slug":"potassium-iodide","display_name":"Potassium iodide","entity_type_key":"chemical_species"}},{"dimension":"plain_language","value_text":"The lower-methimazole comparison also showed faster control.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease. · 2010 · https://pubmed.ncbi.nlm.nih.gov/19912243/ · DOI 10.1111/j.1365-2265.2009.03745.x","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"a7a6c1b1-8b28-5ccf-bb36-e6c6d16bc959","evidence_kind":"source_excerpt","locator":"Lines 392-398","start_line":392,"end_line":398,"excerpt":"## ki-mmi15\nThe lower-methimazole comparison also showed faster control.\nWith MMI 15 mg, two-week FT4 normalization was 54% with KI versus 27% without it.\nModel: 134 untreated Graves patients randomized to MMI 15 or 30 mg, with or without KI; KI withdrawn after FT4 normalization.\nLimitations: Combination treatment, not KI monotherapy; KI dose not extracted from abstract. Faster biochemical control does not prove lasting remission.\nEvidence location: Primary abstract\nBenefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease. · 2010 · https://pubmed.ncbi.nlm.nih.gov/19912243/ · DOI 10.1111/j.1365-2265.2009.03745.x","model_system":"134 untreated Graves patients randomized to MMI 15 or 30 mg, with or without KI; KI withdrawn after FT4 normalization.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Curation paraphrase; primary evidence location and source kind retained above.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"dc3ce411-f68f-5eb8-87c1-1592665f9cb6","stable_key":"import-79018983-9179-5c1a-8e7a-d6f47a13582b","title":"Potassium iodide: thyroid and non-thyroid mechanisms, interactions and discovery questions (2026-09-18)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-study references, chemical references and label statements individually identified. Not publisher full text.","file_path":"","sha256":"3ff9da818dd7a763a59c6abcff2eaee136d7f887a777034feaa5ba304a8fa6ce","revision_id":"53f2ae88-8a91-5326-ac49-3bb510ca78c3","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}